HIGHLIGHTS
- who: Susan Morand and colleagues from the Department of Medicine, University of Toledo, Toledo, OH, USA have published the Article: Ovarian Cancer Immunotherapy and Personalized Medicine, in the Journal: (JOURNAL)
- what: The study was discontinued prior to completion according to predetermined futility boundaries and failure to demonstrate improvement in PFS compared to control (11.1 months, 11.0 months, and 10.2 months, respectively across arms) . This study reported a significant elevation of interferon-gamma (IFN-γ) T-cell frequency in patients after treatment (p=0.00003) and corresponded with a clinical benefit. This study shows . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.